
SeaSpine commenced full commercial launch of OsteoTorrent and OsteoTorrent C, new Accell Demineralized Bone Matrix (DBM) Putties packaged and sterilized in a dry state and designed to further improve osteoinductive potential and shelf-life, while allowing surgeons to reconstitute with saline, blood or bone marrow aspirate.
The OsteoTorrent product families build on SeaSpine’s Evo3®/OsteoSurge® 300 DBMs. OsteoTorrent provides the same handling as Evo3; it packs into gaps and ensures that the graft does not migrate, with the additional benefits of a dry DBM.
Tyler Lipschultz, Senior Vice President, Orthobiologics, said that the launch “further demonstrates our R&D team’s scientific discipline to isolate, test, and optimize individual elements to deliver better, more cost-effective DBMs that compete favorably with many of the more expensive bone grafting alternatives.”
Source: SeaSpine
SeaSpine commenced full commercial launch of OsteoTorrent and OsteoTorrent C, new Accell Demineralized Bone Matrix (DBM) Putties packaged and sterilized in a dry state and designed to further improve osteoinductive potential and shelf-life, while allowing surgeons to reconstitute with saline, blood or bone marrow aspirate.
The OsteoTorrent...
SeaSpine commenced full commercial launch of OsteoTorrent and OsteoTorrent C, new Accell Demineralized Bone Matrix (DBM) Putties packaged and sterilized in a dry state and designed to further improve osteoinductive potential and shelf-life, while allowing surgeons to reconstitute with saline, blood or bone marrow aspirate.
The OsteoTorrent product families build on SeaSpine’s Evo3®/OsteoSurge® 300 DBMs. OsteoTorrent provides the same handling as Evo3; it packs into gaps and ensures that the graft does not migrate, with the additional benefits of a dry DBM.
Tyler Lipschultz, Senior Vice President, Orthobiologics, said that the launch “further demonstrates our R&D team’s scientific discipline to isolate, test, and optimize individual elements to deliver better, more cost-effective DBMs that compete favorably with many of the more expensive bone grafting alternatives.”
Source: SeaSpine
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.






